MX2021007485A - Formulaciones orales de branaplam. - Google Patents

Formulaciones orales de branaplam.

Info

Publication number
MX2021007485A
MX2021007485A MX2021007485A MX2021007485A MX2021007485A MX 2021007485 A MX2021007485 A MX 2021007485A MX 2021007485 A MX2021007485 A MX 2021007485A MX 2021007485 A MX2021007485 A MX 2021007485A MX 2021007485 A MX2021007485 A MX 2021007485A
Authority
MX
Mexico
Prior art keywords
branaplam
oral formulations
tetramethylpiperidin
pyridazin
pyrazol
Prior art date
Application number
MX2021007485A
Other languages
English (en)
Spanish (es)
Inventor
Claire Haug
Gomes Dos Santos Paulo Antonio Fernandes
Rohit Lowalekar
RASPIDE Manaud DE
Thomas Faller
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2021007485A publication Critical patent/MX2021007485A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
MX2021007485A 2018-12-21 2019-12-18 Formulaciones orales de branaplam. MX2021007485A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201811048667 2018-12-21
PCT/IB2019/061038 WO2020128915A1 (en) 2018-12-21 2019-12-18 Oral formulations of branaplam

Publications (1)

Publication Number Publication Date
MX2021007485A true MX2021007485A (es) 2021-08-05

Family

ID=69165436

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007485A MX2021007485A (es) 2018-12-21 2019-12-18 Formulaciones orales de branaplam.

Country Status (14)

Country Link
US (1) US20220071996A1 (pt)
EP (1) EP3897576A1 (pt)
JP (1) JP2022513976A (pt)
KR (1) KR20210107038A (pt)
CN (1) CN113226285A (pt)
AR (1) AR117719A1 (pt)
AU (1) AU2019404930A1 (pt)
BR (1) BR112021011744A2 (pt)
CA (1) CA3119084A1 (pt)
CL (1) CL2021001621A1 (pt)
IL (1) IL283593A (pt)
MX (1) MX2021007485A (pt)
TW (1) TW202038908A (pt)
WO (1) WO2020128915A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202304446A (zh) * 2021-03-29 2023-02-01 瑞士商諾華公司 剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途
WO2024015518A1 (en) * 2022-07-13 2024-01-18 Inaya Therapeutics, Inc. Inhalable imatinib formulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
MY174339A (en) 2012-08-13 2020-04-09 Novartis Ag 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions

Also Published As

Publication number Publication date
WO2020128915A1 (en) 2020-06-25
CN113226285A (zh) 2021-08-06
TW202038908A (zh) 2020-11-01
IL283593A (en) 2021-07-29
CA3119084A1 (en) 2020-06-25
BR112021011744A2 (pt) 2021-08-31
KR20210107038A (ko) 2021-08-31
CL2021001621A1 (es) 2022-02-11
JP2022513976A (ja) 2022-02-09
EP3897576A1 (en) 2021-10-27
AU2019404930A1 (en) 2021-06-03
US20220071996A1 (en) 2022-03-10
AR117719A1 (es) 2021-08-25

Similar Documents

Publication Publication Date Title
MX2016010213A (es) Formulaciones farmaceuticas novedosas.
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
NZ742220A (en) Pharmaceutical compositions comprising meloxicam
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
AU2018231044A8 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MY194087A (en) Use of gabaa receptor reinforcing agent in preparation of sedative and anesthetic medicament
BR112017027843A2 (pt) formulações farmacêuticas compreendendo tenofovir e emtricitabina
MX2019001322A (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
PH12020550341A1 (en) Niraparib formulations
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
AR100663A1 (es) Formulaciones de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona
EA202092829A1 (ru) Композиции тофацитиниба с контролируемым высвобождением
WO2019087083A3 (en) Oral delivery of glp-1 peptide analogs
MX2021007485A (es) Formulaciones orales de branaplam.
EP3500291A4 (en) FORMULATIONS FOR THE ORAL ADMINISTRATION OF ACTIVE AGENTS
PH12019500154A1 (en) Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
PH12017501829A1 (en) Pharmaceutical formulations
EP4282414A3 (en) Modified release tablet formulations containing phosphodiesterase inhibitors
IN2013MU01177A (pt)
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
EA201890929A1 (ru) Низкие дозировки композиций дипиридамола для перорального приема и их использование
MX2019015869A (es) Nuevas formulaciones orales de belinostat.